Dib, E. G., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Ahn, E., Alva, A. S., … Schilsky, R. L. (2024). Pertuzumab plus trastuzumab (P plus T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Dib, Elie G., Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene Ahn, Ajjai Shivaram Alva, Navid Hafez, et al. “Pertuzumab plus trastuzumab (P plus T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Dib EG, Rothe M, Mangat PK, Garrett-Mayer E, Ahn E, Alva AS, et al. Pertuzumab plus trastuzumab (P plus T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Dib, Elie G., et al. “Pertuzumab plus trastuzumab (P plus T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Dib EG, Rothe M, Mangat PK, Garrett-Mayer E, Ahn E, Alva AS, Hafez N, Hobbs E, Akce M, Behl D, Calfa CJ, McKean M, Meric-Bernstam F, Thota R, Watson AP, Yost KJ, Gregory A, Halabi S, Schilsky RL. Pertuzumab plus trastuzumab (P plus T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2024.